After 100% gain since Nov, can the rally in Gland Pharma stock continue?

Gland's prospects remain strong, say analysts, as it has a robust pipeline of products with 50 pending Abbreviated New Drug Applications (ANDAs) and a healthy filing rate of 21 ANDAs in 9MFY21

Gland Pharma has already doubled money for those investors who picked the stock at the time of its initial public offering (IPO) in November 2020. And now, the firm's March quarter results have convinced analysts of more upside as they see growth prospects for Gland going ahead.

On Tuesday, the stock hit an all-time high of Rs 3,124.75 on the BSE, up 12 per cent over its previous close, following a 34 per cent year-on-year (YoY) rise in its consolidated net profit to Rs 260.4 crore in the March 2021 quarter (Q4FY21) on robust sales. The stock has